IDEAYA Entered into a Clinical Trial Collaboration and Supply Agreement with Amgen for IDE397 + AMG 193 in MTAP Deleted Solid Tumors
Shots:
- The companies collaborated to evaluate the efficacy & safety of IDE397 (MAT2A inhibitor) + AMG 193 (MTA-cooperative inhibitor of PRMT5) in a P-I trial for solid tumors with MTAP deletion. Both companies obtain all commercial rights to compounds as monothx. or combination therapies
- Amgen will sponsor the P-I trial & will receive IDE397 drug supply. IDEAYA will lead the early clinical development of IDE397 with GSK. If GSK exercises its option, it will lead to later-stage development of IDE397
- Both companies will share the costs of the study & will oversee the clinical development of the combination therapy. IDEAYA has initiated the P-I study of IDE397 as monothx. & in combination with docetaxel in NSCLC, paclitaxel in esophagogastric cancer & pemetrexed in NSCLC
Ref: PRNewswire | Image: IDEAYA
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
